Zusammenfassung
Die immunologische Abstoßungsreaktion ist der wichtigste Grund für ein Transplantatversagen nach Hornhauttransplantation. Ohne systemische Immunsuppression kommt es in einer Hochrisikosituation in über 50% der Fälle zu einer Eintrübung des Transplantats innerhalb des ersten postoperativen Jahres. Die klonale Expansion von alloreaktiven Lymphozyten findet in lymphoiden Organen statt. Da topische Steroide die sekundären lymphatischen Gewebe nicht erreichen und auch systemische Steroide nicht ausreichend die klonale Expansion von aktivierten T-Zellen unterdrücken, ist der Einsatz von systemischen Immunsuppressiva unumgänglich, um ein klares Transplantatüberleben zu erreichen. Es ist allerdings besonders nach Hochrisikokeratoplastik, einer nicht lebensrettenden Transplantation wichtig, die Vor- und Nachteile einer immunsuppressiven Therapie abzuwägen.
Abstract
Immunologic rejection is the main cause of corneal graft failure. If corneal transplantation is performed in a high-risk situation without the use of systemic immunosuppression, corneal graft failure has to be expected in over 50% of patients within the first postoperative year. The clonal expansion of graft-specific lymphocytes occurs in lymphoid tissues. As topical steroids do not reach the secondary lymphoid organs, and even systemic steroids do not interfere sufficiently with the clonal expansion of activated T cells, it is essential to administer systemic immunosuppressives in order to achieve clear graft survival. As corneal transplantation is not a life-saving procedure, the profile of side-effects is a central issue when choosing an immunosuppressive medication.
Literatur
Allison A, Hovi R, Watts A et al. (1977) The role of de novo purine synthesis in lymphocyte transformation. Ciba Found Symp 48: 207
Benelli U, Lepri A, Del-Tacca M et al. (1996) FK-506 delays corneal graft. J Ocul Pharmacol Ther 12: 425–431
Birnbaum F, Reinhard T, Bohringer D et al. (2005) Endothelial cell loss after autologous rotational keratoplasty. Graefes Arch Clin Exp Ophthalmol 243: 57–59
Brattstrom C, Tyden G, Sawe J et al. (1996) A randomized, double-blind, placebo-controlled study to determine safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients. Transplant Proc 28: 985–986
Bussutil RW, Holt CD (1997) Tacrolimus (FK506) is superior to cyclosporine in liver transplantation. Transplant Proc 29: 534–538
Chen YF, Gebhardt BM, Reidy JJ et al. (1990) Cyclosporine-containing collagen shields suppress corneal allograft rejection. Am J Ophthalmol 109: 132–137
Crowe A, Lemaire M (1998) In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with rapamycin. Pharm Res 15: 1666–1672
Deierhoi M, Sollinger H, Diethelm A et al. (1993) One-year follow-up results of a phase 1 trial of mycophenolate mofetil (RS-61443) in cadaveric renal transplantation. Transplant Proc 25: 693
Dickey JB, Cassidy EM, Bouchard CS (1993) Periocular FK-506 delays allograft rejection in rat penetrating keratoplasty. Cornea 12: 204–207
Eisen HJ, Tuzcu EM, Dorent R et al. (2003) Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant Recipients. N Engl J Med 349: 847–858
European Mycophenolate Mofetil Cooperative Study Group (1995) Placebo controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for the prevention of acute rejection. The Lancet 345: 1321–1325
Mayer K, Birnbaum F, Reinhard T et al. (2004) FTY720 prolongs clear corneal allograft survival with a differential effect on different lymphocyte populations. Br J Ophthalmol 88: 915–919
Hikita N, Lopez JS, Chan C et al. (1997) Use of topical FK506 in a corneal graft rejection model in lewis rats. Invest Ophthalmol Vis Sci 38: 901–909
Hill JC, Maske R (1988) An animal model for corneal graft rejection in high-risk keratoplasty. Transplantation 46: 26–30
Hill JC (1995) Systemic cyclosporine in high-risk keratoplasty: long-term results. Eye 9: 422–428
Hoffmann F, Wiederholt M (1986) Topical cyclosporin A in the treatment of corneal graft reaction [editorial]. Cornea 5: 129
Kino T, Hatayama H, Hashimoto M et al. (1987) FK-506, a novel immunosuppressant isolated from Streptomyces: 1: Fermentation, isolation, and physio-chemical and biological characteristics. J Antibiot 40: 1249–1255
Lakkis FG, Arakelov A, Koniecny BT et al. (2000) Immunologic „ignorance“ of vascularized organ transplants in the absence of secondary lymphoid tissue. Nat Med 6: 686–688
Mayer K, Reinhard T, Reis A et al. (2003) Synergistic antiherpetic effect of acyclovir and mycophenolate mofetil following keratoplasty in patients with herpetic eye disease: first results of a randomised pilot study. Graefes Arch Clin Exp Ophthalmol 241: 1051–1054
Mayer K, Birnbaum F, Reinhard T et al. (2004) FTY720 prolongs clear corneal allograft survival with a differential effect on different lymphocyte populations. Br J Ophthalmol 88: 915–919
Mills RA, Jones DB, Winkler CR et al. (1995) Topical FK-506 prevents experimental corneal allograft rejection. Cornea 14: 157–160
Minamoto A, Sakata H, Okada K et al. (1995) Suppression of corneal graft rejection by subconjunctival injection of FK-506 in a rat model of penetrating keratoplasty. Jpn J Ophthalmol 39: 12–19
Morris R, Hoyt E, Murphy P (1990) Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selevtive inhibition of T- and B-cell purine synthesis. Transplant Proc 22: 1659
Morris RE, Huang X, Gregory CR et al. (1995) Berry-Studies in experimental models of chronic rejection: use of rapamycin (sirolimus) and isoxazole derivatives (leflunomide and its analogue) for the suppression of graft vascular disease and obliterative bronchiolitis. Transplant Proc 27: 2068–2069
Murgia MG, Jordan S, Kahan BD (1996) The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 49: 209–216
Olsen TW, Benegas NM, Joplin AC et al. (1994) Rapamycin inhibits corneal allograft rejection and neovascularization. Arch Ophthalmol 112: 1471–1475
Otto Ch, Ulrichs K (2004) The immunology of allograft rejection. Tx Med 16: 158–171
Perry HD, Donnenfeld ED, Acheampong A et al. (1998) Topical Cyclosporine A in the management of postkeratoplasty glaucoma and corticosteroid-induced ocular hypertension (CIOH) and the penetration of topical 0.5% cyclosporine A into the cornea and anterior chamber. CLAO J 24: 159–165
Reinhard T, Bohringer D, Enzmann J et al. (2004) HLA class I/II matching and chronic endothelial cell loss in penetrating normal risk keratoplasty. Acta Ophtahmol Scand 82: 13–18
Reinhard T, Kontopoulos T, Wernet P et al. (2004) Long-term results of homologous penetrating limbokeratoplasty in total limbal stem cell insufficiency after chemical/thermal burns. Ophthalmologe 101: 682–687
Reinhard T, Moller M, Sundmacher R (1999) Penetrating keratoplasty in patients with atopic dermatitis with and without systemic cylocsporin A. Cornea 18: 645–651
Reinhard T, Sundmacher R, Godehardt E et al. (1997) [Preventive systemic cyclosporin A after keratoplasty at increased risk for immune reactions as the only elevated risk factor] Systemische Cyclosporin-A-Prophylaxe nach Keratoplastiken mit erhohtem Risiko fur Immunreaktionen als einzigem erhohten Risikofaktor. Ophthalmologe 94: 496–500
Reinhard T, Sundmacher R (1996) Local cyclosporin A therapy in Thygeson superficial punctate keratitis–a pilot study. Klin Monatsbl Augenheilkd 209: 224–227
Reinhard T, Sundmacher R (1992) Perforating keratoplasty in endogenous eczema. An indication for systemic cyclosporin A–a retrospective study of 18. Klin Monatsbl Augenheilkd 201: 159–163
Reinhard T, Sundmacher R (1999) Topical Cyclosporin A in Thygeson‚s superficial punctate keratitis. Graefes Arch Clin Exp Ophthalmol 237: 109–112
Reis A, Megahed M, Reinhard T et al. (2001). RAD, a new immunosuppressive macrolide in murine corneal transplantation. Graefes Arch Clin Exp Ophthalmol 239: 689–692
Reis A, Megahed M, Reinhard T et al. (2002) Synergism of RAD and cyclosporin A in prevention of acute rat corneal allograft rejection. Cornea 21: 81–84
Reis A, Megahed M, Reinhard T et al. (2000) Coadministration of the new macrolide immunosuppressant RAD and mycophenolate mofetil in experimental corneal transplantation. Transplantation 70: 1397–1401
Reis A, Reinhard T, Sundmacher R et al. (1998) [Mycophenolatemofetil in ocular immunological disorders. A survey of the literature with 3 case reports], Mycophenolatmofetil (CellCept) bei okularen immunologischen Storungen. Literaturubersicht mit 3 Kasuistiken. Klin Monatsbl Augenheilkd 213: 257–261
Reis A, Reinhard T, Sundmacher R et al. (1998) Effect of mycophenolate mofetil, cyclosporin A, and both in combination in a murine corneal graft rejection model. Br J Ophthalmol 82: 700–703
Reis A, Reinhard T, Sundmacher R et al. (1998) A Comparative Investigation of the Effect of FK506 (Prograf®) and Cyclosporin A (Sandimmun®, CSA) In Murine Corneal Transplantation. Graefes Arch Clin Exp Ophthalmol 236: 785–789
Reis A, Reinhard T, Sundmacher R et al. (1998) FK506 and Mycophenolatemofetil: Two novel immunosuppressants in murine corneal transplantation. Transpl Proc 30: 44
Reis A, Reinhard T, Voiculescu A et al. (1999) Mycophenolatemofetil versus Cyclosporin A in high-risk keratoplasty patients: A prospectively randomized clinical trial. Br J Ophthalmol 83: 1268–1271
Sawada S, Suzuki G, Kawase Y et al. (1987) Novel immunosuppressive agent, FK-506: In vitro effects on the cloned T cell activation. J Immunol 40: 1249–1255
Schmitz K, Hitzer S, Behrens-Baumann W (2002) Immune suppression by combination therapy with basiliximab and cyclosporin in high risk keratoplasty. A pilot study. Ophthalmologe 99: 38–45
Schuurman HJ, Schuler W, Ringers J et al. (1998) The macrolide SDZ RAD is efficacious in a nonhuman primate model of allotransplantation. Transplant Proc 30: 2198–2199
Simmons WD, Rayhill SC, Sollinger HW (1997) Preliminary risk-benefit assessment of mycophonlate mofetil in transplant rejection. Drug Safety 17: 75–92
Sloper CM, Powell RJ, Dua HS (2001) Tacrolimus (FK506) in the management of high-risk corneal and limbal grafts. Ophthalmology 108: 1838–1844
Streilein JW, Okamoto S, Sano Y, Taylor AW (2000) Neural control of ocular immune privilege. Ann NY Acad Sci 917: 297–306
The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group (1996) A blinded, randomized clinical trial of mycophnolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 61: 1029–1037
Thompson P, Xu D, Brunette I, Chen H (1998) Combined effect of rapamycin and cyclosporine in the prevention of rat corneal allograft rejection. Transplant Proc 30: 1033–1035
Vu MD, Qi S, Xu D et al. (1998). Synergistic effects of mycophenolate mofetil and sirolimus in prevention of acute heart, pancreas, and kidney allograft rejection and in reversal of ongoing heart allograft rejection in the rat. Transplantation 66: 1575–1580
Woodle ES, Thistlethwaite JR, Gordon JH (1996) For the FK506 Kidney Transplant Rescue Study Group: A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. Transplantation 62: 594–599
Yoshimura N, Matsui S, Hamashima T et al. (1989). Effects of a new immunosuppressive agent, FK-506, on human lymphocyteresponsiveness in vitro: 1: Inhibition of expression of alloantigen-activated suppressor cells, as well as induction of alloreactivity. Transplantation 47: 351–356
Interessenkonflikt
Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Reis, A., Birnbaum, F. & Reinhard, T. Systemische Immunsuppressiva nach perforierender Keratoplastik. Ophthalmologe 104, 373–380 (2007). https://doi.org/10.1007/s00347-007-1517-x
Issue Date:
DOI: https://doi.org/10.1007/s00347-007-1517-x